A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ESTIMATE THE EFFECT OF PF-07081532 ADMINISTRATION ON THE SINGLE-DOSE PHARMACOKINETICS OF DABIGATRAN AND ROSUVASTATIN IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS

The purpose of the study was to understand the effect of PF-07081532 on the movement of Dabigatran and Rosuvastatin into, though, and out of the body in healthy overweight or obese adult participants. This study also aims to collect data on safety and how tolerable the study medicine is.
The study is seeking for participants who are:
* Male or female who are 18 years of age or older.
* Healthy but are overweight or obese. Participants will receive dabigatran and rosuvastatin as single doses by mouth 3 times during the study. The amount of the study medicine PF-07081532 will be adjusted over time until any interactions are seen.
PF-07081532 is taken daily by mouth in 8 Study Periods while admitted into the study clinic over 53 days. Once discharged from the study clinic, participants will have a follow-up visit 7 to 10 days post last dose of study medicine. Then another follow-up via telephone contact, 28 to 35 days post last dose of study medicine.

Start Date27 Mar 2023

Sponsor / Collaborator

Pfizer Inc.

NCT05745701

/ CompletedPhase 1

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF ITRACONAZOLE AND CYCLOSPORINE ON THE SINGLE-DOSE PHARMACOKINETICS OF PF-07081532 IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS

This is a Phase 1, open-label, fixed-sequence, 3-period study to evaluate the effect of multiple doses of itraconazole and a single dose of cyclosporine on the single-dose PK of PF-07081532 in otherwise healthy, overweight or obese, adult female and male participants.
The 3 study periods will be conducted consecutively without a break.

Start Date22 Feb 2023

Sponsor / Collaborator

Pfizer Inc.

NCT05671653

/ TerminatedPhase 1

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO EVALUATE THE EFFECT OF TWO STEADY-STATE DOSE LEVELS OF PF-07081532 ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, OMEPRAZOLE AND AN ORAL CONTRACEPTIVE, AND THE EFFECT OF STEADY-STATE SEMAGLUTIDE ON THE PHARMACOKINETICS OF SINGLE-DOSE MIDAZOLAM, IN OBESE ADULT FEMALE PARTICIPANTS

Two different groups of healthy volunteers will be chronically treated with GLP-1 drugs PF-07081532 or alternatively Semaglutide. The effect of these GLP-1 drugs on a single dose of the common sedative medication midazolam blood levels will be measured. The effect of chronic PF-07081532 on single doses of the common stomach acid medication omeprazole, and common birth control medication blood levels will also be measured. The hypothesis is that chronic administration of the GLP-1 drugs will minimally affect blood levels from these common medications.

Start Date19 Jan 2023

Sponsor / Collaborator

Pfizer Inc.

100 Clinical Results associated with Lotiglipron

100 Translational Medicine associated with Lotiglipron

100 Patents (Medical) associated with Lotiglipron

Literatures (Medical) associated with Lotiglipron

01 Jan 2025·DIABETES OBESITY & METABOLISM

Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study

Article

Author: Buckley, Gina ; Vasas, Szilard ; Frederich, Robert ; Haggag, Amina Z. ; Amin, Neeta B. ; Palmer, Alexandra ; Zhu, Qi ; Tsamandouras, Nikolaos ; DuBrava, Sarah J. ; Johnson, Margot ; Schuster, Tilman ; Zmuda, Witold ; Smith, Timothy R.

Abstract:

Aim:

The aim was to investigate the effects of lotiglipron, a once‐daily, oral small‐molecule glucagon‐like peptide‐1 (GLP‐1) receptor agonist, in participants with type 2 diabetes (T2D) or obesity.

Materials and Methods:

A phase 2, randomized, double‐blind, placebo‐controlled, dose‐ranging study investigated the efficacy and safety of lotiglipron. The study was terminated early for safety reasons after routine data and monitoring review. The planned analyses for the end points were modified prior to unblinding the study.

Results:

In total, 901 participants were treated with at least one dose of the study drug (T2D cohort: n = 512, obesity cohort: n = 389). Although the majority of participants who were randomly assigned to higher doses did not reach their target maintenance dose, statistically significant changes in HbA1c and body weight were observed. In the T2D cohort, reductions in HbA1c were observed across all lotiglipron doses at week 16 (p < 0.0001), with least squares mean decreases up to −1.44% (90% confidence interval [CI]: −1.63, −1.26) (lotiglipron 80 mg), versus placebo, −0.07% (90% CI: −0.25, 0.11). In the obesity cohort, decreases in body weight were observed across all lotiglipron doses at week 20 (p < 0.01), up to −7.47% (90% CI: −8.50, −6.43) (lotiglipron 200 mg, five‐step titration), versus placebo, −1.84% (90% CI: −2.85, −0.83). Across cohorts, the most frequently reported treatment‐emergent adverse events were gastrointestinal related (most mild to moderate severity), with nausea being the most common (ranging from 4% [placebo] to 28.8% [80 mg] in the T2D cohort and 12.5% [placebo] to 60.6% [200 mg, four‐step titration] in the obesity cohort). Transaminase elevations were observed in a subset of participants (6.6% and 6.0% of participants on lotiglipron in the T2D and obesity cohorts, respectively, compared with 1.6% on placebo in the obesity cohort).

Conclusions:

The efficacy (HbA1c and/or body weight) of a range of lotiglipron doses was demonstrated in T2D and obesity cohorts. The safety profile was largely consistent with what has been previously known about the mechanism of action. Our results are unique in reporting elevations in liver transaminases in a subset of participants treated with lotiglipron, with attempts to identify the at‐risk population unsuccessful and therefore clinical development of lotiglipron terminated.

ClinicalTrials.gov:

NCT05579977.

18 Dec 2024·Science Translational Medicine

The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron

Article

Author: Willard, Francis S. ; Suter, Todd M. ; Emmerson, Paul J. ; Padgett, Leah R. ; White, Alex ; O’Farrell, Libbey S. ; Hewitt, Natalie ; Peterson, Jeffrey A. ; Sangwung, Panjamaporn ; Liu, Zhaomin ; Ruble, J. Craig ; Wainscott, David B. ; Coskun, Tamer ; Cox, Amy L. ; Showalter, Aaron D. ; Sloop, Kyle W. ; Snider, Brandy M. ; Dunbar, James D. ; Coutant, David E. ; Stutsman, Cynthia ; Woerly, Eric M. ; Ai, Minrong ; Droz, Brian A.

Orally bioavailable, synthetic nonpeptide agonists (NPAs) of the glucagon-like peptide-1 receptor (GLP-1R) may offer an effective, scalable pharmacotherapy to address the metabolic disease epidemic. One of the first molecules in the emerging class of GLP-1R NPAs is orforglipron, which is in clinical development for treating type 2 diabetes and obesity. Here, we characterized the pharmacological properties of orforglipron in comparison with peptide-based GLP-1R agonists and other NPAs. Competition binding experiments using either [ 125 I]GLP-1(7-36)NH 2 or [ 3 H]orforglipron indicated that orforglipron is a high-affinity [inhibition constant ( Ki ) = 1 nM], selective ligand of the human GLP-1R. Signal transduction assays showed that orforglipron has low intrinsic efficacy for effector activation and negligible β-arrestin recruitment. To evaluate GLP-1R engagement in vivo, mice expressing the human GLP-1R were administered orforglipron and subjected to a glucose tolerance test. Predicted receptor occupancy was calculated using the receptor Ki value of orforglipron and its unbound concentration in vivo that reduces hyperglycemia. These experiments revealed that low GLP-1R occupancy by orforglipron is sufficient to yield a full biological response. Moreover, in a model where CRISPR-Cas9 gene editing was used to sensitize the rat GLP-1R ( Glp1r S33W ) to GLP-1R NPAs, target engagement by orforglipron in the pancreas and brain was consistent with peptide-based GLP-1R agonists. Diet-induced obesity in Glp1r S33W rats enabled studies showing weight loss in animals orally administered orforglipron versus subcutaneous injection of GLP-1R agonist semaglutide. Furthermore, crossover studies indicated oral orforglipron can sustain efficacy initiated by parenteral semaglutide. The pharmacological properties of orforglipron may inform targeting of other peptide receptors with NPAs.

01 Aug 2024·DIABETES OBESITY & METABOLISM

Once‐daily oral small‐molecule glucagon‐like peptide‐1 receptor agonist lotiglipron (PF‐07081532) for type 2 diabetes and obesity: Two randomized, placebo‐controlled, multiple‐ascending‐dose Phase 1 studies

Article

Author: Tsamandouras, Nikolaos ; Brown, Lisa S. ; Saxena, Aditi R. ; Carvajal‐Gonzalez, Santos ; Buckeridge, Clare ; Hernandez‐Illas, Martha

Abstract:

Aim:

To investigate the effects of lotiglipron (PF‐07081532), a once‐daily, oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in participants with type 2 diabetes (T2D) and/or obesity.

Materials and Methods:

Two Phase 1 randomized, double‐blind, placebo‐controlled, multiple‐ascending‐dose studies were conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of lotiglipron.

Results:

Across the studies, 74 participants with T2D were treated for 28 or 42 days, and 26 participants with obesity without diabetes were treated for 42 days, following randomization to placebo or lotiglipron (target doses 10–180 mg/day, with dose titration to higher target doses). Most adverse events were mild (89.6%), with nausea the most frequently reported in both studies. There were no clinically meaningful adverse trends noted in safety laboratory tests, vital signs, or electrocardiogram parameters. In participants with T2D, lotiglipron resulted in dose‐dependent reductions in mean daily glucose. The 180‐mg dose was associated with least squares mean decreases from baseline in glycated haemoglobin (−1.61% [90% confidence interval {CI} –2.08, −1.14] vs. −0.61% [−1.56, 0.34] for placebo) and body weight (−5.10 kg [90% CI –6.62, −3.58] vs. −2.06 kg [90% CI –4.47, 0.36] for placebo) after 42 days; a similar magnitude of weight loss was seen in participants with obesity. The observed pharmacokinetic profile supported once‐daily dosing.

Conclusions:

The profile of once‐daily lotiglipron with doses up to 180 mg, as observed in these two Phase 1 studies, indicated a safety and tolerability profile consistent with the mechanism of action, with dose‐dependent reductions in glycaemic indices (T2D) and body weight (both populations) after multiple doses. Clinicaltrials.gov identifier: NCT04305587, NCT05158244.

News (Medical) associated with Lotiglipron

14 Apr 2025

·www.biospace.com

Pfizer Drops Lead Obesity Asset After Liver Safety Concerns, Overall Review

iStock, cagkansayin Pfizer’s discontinuation of danuglipron brings the company down to a single molecule in its obesity pipeline. Pfizer will no longer invest in the development of its oral GLP-1 drug danuglipron after the pharma detected a potential case of drug-induced liver injury, the company announced on Monday. “Although danuglipron is not Pfizer’s only obesity asset, today’s update sends the company back to the starting block,” BMO Capital Markets wrote in a note Monday morning. Pfizer maintained that the patient with liver injury, which was detected during dose-optimization studies, was asymptomatic and that the complication “resolved after discontinuation of danuglipron.” The pharma added that in more than 1,400 patients treated so far, the overall occurrence of liver enzyme elevations was “in-line” with other approved therapies in this class. Still, Pfizer has decided to discontinue danuglipron “after a review of the totality of information, including all clinical data generated to date … and recent input from regulators.” With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog PF-07976016, which is currently in Phase II development . According to a federal clinical trials register , the study has an initial completion date of December 2025. Like other drugs in its class—such as Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound—danuglipron works by targeting and activating the GLP-1 receptor, in turn promoting the secretion of insulin in response to spikes in blood sugar. Danuglipron also slows the emptying of the stomach, helping to suppress hunger and appetite. Despite that well-characterized mechanism of action, danuglipron has struggled to prove its value in the clinic. In December 2023, Pfizer announced that it would no longer be testing danuglipron as a twice-daily pill after it saw high rates of side effects in a Phase IIb study. Up to 73% of treated patients experienced nausea, while roughly 47% and 25% developed vomiting and diarrhea, respectively. Discontinuation as a result of side effects was high, reaching over 50% across all danuglipron doses, Pfizer revealed at the time. A few months later, in July 2024, the pharma said it had tweaked danuglipron’s formulation and would continue advancing the drug as a once-daily pill. This move brought danuglipron back to Phase I testing, though the setback didn’t seem to shake the pharma’s commitment to weight loss. At the 2025 J.P. Morgan Healthcare Conference in January, CEO Albert Bourla reiterated that Pfizer would go “all in” on obesity and has even brought in additional experts to help with decision-making, though he tempered investors’ expectations of danuglipron, noting that he is “very cautious” about the asset. William Blair had an idea for Pfizer. In a Monday morning note, analysts called “Pfizer’s setback . . . an invigorating development for Viking’s shareholders. Specifically, they said, “VK2735 could offer Pfizer a rare opportunity to reestablish not only a mere presence in obesity, but also a leading position beyond” the current Novo Nordisk/Eli Lilly duopoly. Danuglipron isn’t Pfizer’s first failed weight-loss drug. In June 2023, the company axed lotiglipron, another GLP-1 therapy, which it had been testing for obesity and type 2 diabetes. Lotiglipron was also associated with liver safety issues, particularly elevated levels of transaminases.

Phase 2Phase 1Clinical Result

14 Apr 2025

·www.pharmaceutical-technology.com

Pfizer drops obesity pill development after liver injury report

The new plant is intended to support Pfizer’s gene therapy research and development. Credit: Lauri Silvennoinen. Pfizer has terminated the development of its oral obesity candidate danuglipron after a patient on a clinical trial with the drug suffered a liver injury. The oral glucagon-like peptide-1 receptor agonist (GLP-1RA) was being investigated in chronic weight management in several Phase I and Phase II trials . Two Phase I studies (NCT06567327 and NCT06568731) met pharmacokinetic (PK) endpoints and determined a formulation and dose for danuglipron. In one of these studies, an asymptomatic patient experienced a potential drug-induced liver injury. The injury resolved after drug discontinuation; however, Pfizer has decided, based on this event, available clinical data, and recent input from regulators to discontinue the development of the drug. The therapy has been investigated in a total of 1,400 patients. Chief scientific officer and president of R&D at Pfizer, Dr. Chris Boshoff said: “While we are disappointed to discontinue the development of danuglipron, we remain committed to evaluating and advancing promising programs in an effort to bring innovative new medicines to patients.” Pfizer will be presenting data from the studies at an upcoming medical conference and peer-reviewed journal. Pfizer still pushing in obesity space Unlike some of its big pharma competitors, Pfizer has not had much luck in the obesity pill space. In December 2023, the company stopped the development of the twice-daily version of danuglipron due to high rates of gastrointestinal side effects . This came six months after the company had culled another oral GLP-1-RA candidate, lotiglipron , due to associated high transaminase levels. The company still has another oral obesity candidate in trials, a once daily glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, PF-07976016. The therapy is being investigated in a Phase IIa trial (NCT06717425), which was initiated in December 2024. Pfizer faces fierce competition in the obesity space, especially from Novo Nordisk and Eli Lilly, both of which have cemented a reputation with their subcutaneous GLP-1RA therapies Wegovy (semaglutide) and Zepbound (tirzepatide), respectively. Eli Lilly is also looking to enter the oral obesity space and is running a Phase III programme of its daily pill orforglipron. GlobalData predicts sales of orforglipron to reach $11.8bn in 2030. GlobalData is the parent company of Clinical Trials Arena . Biotechs are also making headway in the obesity arena. Viking Therapeutics is studying an oral version of the weight loss therapy VK2735 in an ongoing Phase II study (NCT06828055), and its subcutaneous formulation is set to enter a Phase III trial in Q2 2025. Pfizer’s stock, listed on the New York Stock Exchange (NYSE), remains stable despite the danuglipron announcement. Meanwhile, Viking’s stock, listed on the Nasdaq exchange, jumped by 21% at market open today (14 April).

Phase 2Phase 1Phase 3Clinical Result

07 Oct 2024

·www.pharmaceutical-technology.com

Activist investor Starboard forges $1bn stake in Pfizer to swing profits

Shares in the company are trading nearly 54% down compared to pandemic-high prices. Image credit: Shutterstock/ ShU studio. Activist investor Starboard Value has built a $1bn stake in Pfizer to seek a turnaround in the drugmaker’s tumbling share price, according to sources familiar with the matter. US hedge fund Starboard has approached former Pfizer CEO Ian Read and recent CFO Frank D’Amelio to help forge a post-pandemic route to profit, as per Wall Street Journal, which originally reported the news. Despite the success of its Covid-19 mRNA vaccine which drove Pfizer’s 2022 revenue to record profits, Pfizer shares have steadily fallen as demand for Covid-19-related products weans . Shares in the company are trading nearly 54% down at the most recent market close compared to its all-time high closing price in December 2021, during the Covid-19 pandemic. Pfizer has a market cap of $162bn. While details of Starboard’s roadmap at Pfizer are unknown, the $1bn stake means the activist investor now holds 0.6% of Pfizer’s value. When reached for comment by Pharmaceutical Technology , a Pfizer spokesperson did not confirm the investment and stated the company does not comment on market speculation or rumours. Activist investors are typically specialist hedge funds that buy a large stake in a publicly traded company to influence how it’s run, with a view to increase the target company’s share price and improve its performance. See Also: Almac Group North American Headquarters Expansion, Pennsylvania, USA LOTTE BIOLOGICS’ East Syracuse Pharmaceutical Manufacturing Facility, US While Pfizer tackles weaker revenue for Covid-19 vaccines and drugs, along with an underwhelming launch of its respiratory syncytial virus (RSV) vaccine Abrysvo, Moderna and GSK have also struggled with their respective RSV vaccine revenues. Pfizer’s attempts to join the lucrative weight loss market have also hit difficulties. The company reworked a twice-daily version of its candidate danuglipron into a once-a-day pill following high rates of side effects in a mid-stage trial. The company had already dropped another daily weight-loss drug, called lotiglipron, due to safety concerns as it raised levels of liver enzymes in some patients. The company also terminated its late-stage Duchenne muscular dystrophy (DMD) drug after a lack of benefit in a Phase III trial and a patient death in Phase II study. Pfizer’s CEO Albert Bourla, who was key in securing the Covid-19 vaccine partnership with BioNTech , admitted in an investor call in January that Pfizer had endured a difficult 2023. Pfizer’s revenue was still ultimately down 41% in 2023, with Bourla taking a 35% reduction in pay during the year. The CEO missed out on a bonus as Pfizer’s 2023 financial performance was “below pre-established targets,” as per the company’s annual report . Bourla stated that the company entered 2024 with a “solid foundation” and that its commitment to the “next wave of pipeline innovation will fuel Pfizer’s growth”. Following Q1 net income declines of 44%, Pfizer announced a cost reduction programme in May this year, expected to save around $1.5bn by 2027. Despite a turbulent financial performance, Pfizer has been active in the M&A market over the past year, with several high-profile deals wrapped up to solidify product lines. The biggest by far was the company’s $43bn takeover of cancer drugmaker Seagen to stake a claim in the burgeoning antibody-drug conjugate market. Pfizer’s acquisition of biotech Global Blood Therapeutics (GBT) was in the spotlight recently, after lead sickle cell disease drug Oxbryta (voxelotor), which was bought as part of the deal, had to be pulled off the market with clinical studies also discontinued due to adverse side effects.

VaccineAcquisitionPhase 2mRNAIPO

100 Deals associated with Lotiglipron

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 2	United States	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Japan	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Bulgaria	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Canada	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Czechia	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Hungary	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Poland	Pfizer Inc.	27 Oct 2022
Diabetes Mellitus, Type 2	Phase 2	Puerto Rico	Pfizer Inc.	27 Oct 2022
Obesity	Phase 2	United States	Pfizer Inc.	27 Oct 2022
Obesity	Phase 2	Japan	Pfizer Inc.	27 Oct 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05788328 (CTgov)	Phase 1	Obesity	16	DE (Period 1: DE 150 mg)	yvfvsdriva(xmihjpftig) = xjwbserapi wwkiggxaup (eskcmmmkqb, 43) View more	-	15 Nov 2024
				DE+PF-07081532 (Period 4: DE 150 mg + PF-07081532 80 mg QD)	yvfvsdriva(xmihjpftig) = ztchxdcgia wwkiggxaup (eskcmmmkqb, 38) View more
NCT05510245 (CTgov)	Phase 1	Diabetes Mellitus, Type 2 \| Functional disorder	18	PF-07081532 (Mild Renal Impairment)	enmowlftdv(cqzrgwhwli) = igksnmkcbz wonwowmqdr (hfjblfqqni, 50) View more	-	05 Nov 2024
				PF-07081532 (Moderate Renal Impairment)	enmowlftdv(cqzrgwhwli) = vnjjbpfiee wonwowmqdr (hfjblfqqni, 24) View more
NCT05652647 (CTgov)	Phase 1	-	6	[14C]PF-07081532 (Period 1: [14C]PF-07081532 30 mg Oral)	gjqrdlgqqe(itvaxxhqnc) = zdzoeuhsad kbjhtjcoet (iqprrroxqa, 0.6) View more	-	24 Sep 2024
				[14C]PF-07081532 (Period 2: PF-07081532 30 mg Oral + [14C]PF-07081532 100 µg IV)	nwcheilaal(esbvyipgro) = ctqeqtdfqs hgsvktvyxi (ttlacnphge, 32) View more
NCT05745701 (CTgov)	Phase 1	Obesity	16	Lotiglipron (Active Comparator: Period 1: Lotiglipron)	ahrsidwpdv(zocidccnfq) = jtxvckzkgp ewvixoffad (joepdbogxx, 49) View more	-	23 Sep 2024
				Cyclosporine+Lotiglipron (Experimental: Period 2: Lotiglipron + Cyclosporine)	ahrsidwpdv(zocidccnfq) = llyvekhmvs ewvixoffad (joepdbogxx, 62) View more
NCT05478603 (CTgov)	Phase 1	Liver Injury	24	PF-07081532 (Without Hepatic Impairment)	tsvkgkscld(xwikoinhkq) = ovikgwohue bmmkfnfrav (wxnfdmldfr, 10) View more	-	22 Aug 2024
				PF-07081532 (Mild Hepatic Impairment)	tsvkgkscld(xwikoinhkq) = yysefxhgol bmmkfnfrav (wxnfdmldfr, 18) View more
NCT05158244 (CTgov)	Phase 1	Diabetes Mellitus, Type 2	34	Placebo (Placebo (Type 2 Diabetes Mellitus [T2DM]))	alnyrjdhaf = guxsybbofg xqyofaainm (hslxioyyvh, gklkojmybk - boywwrqizj) View more	-	12 Aug 2024
				PF-07081532 (PF-07081532 20-60 mg (T2DM))	alnyrjdhaf = olcpvoqiqt xqyofaainm (hslxioyyvh, xjxfpfhhie - udxylbufjj) View more
NCT05158244 \| NCT04305587 (Pubmed) Manual	Phase 1	Diabetes Mellitus, Type 2 \| Obesity	74	Lotiglipron 10mg/day	baaorfkkei(diecetobpg) = Most adverse events were mild (89.6%), with nausea the most frequently reported in both studies. xcgoomtlis (ifydgilgif )	Positive	01 Aug 2024
				lotiglipron 180-mg (T2D)
NCT04305587 (Phase 1, CTgov)	Phase 1	Diabetes Mellitus, Type 2	66	Placebo (Placebo Part A)	qkuculmhsm = ewdhnukogf aoqkphdpxo (miwehmusxo, uzoqeposya - kvfsusenfj) View more	-	05 Feb 2024
				PF-07081532 (PF-07081532 10 mg Part A)	qkuculmhsm = khysvmecrf aoqkphdpxo (miwehmusxo, dybuogjydd - ryhcmazhgw) View more
NCT04305587 (Phase 1, EASD2022)	Phase 1	Diabetes Mellitus, Type 2 \| Obesity	-	PF-07081532	wkhhqhvcue(gvksxnxmss) = Most adverse events were mild and consistent with the mechanism of action. No clinically significant, adverse trends in laboratory measures, electrocardiogram or vital sign abnormalities were apparent. qeaehsflwk (umohnwjmco )	Positive	21 Sep 2022
NCT05158244 (Corporate Publications) Manual	Phase 1	Diabetes Mellitus, Type 2	34	PF 07081532	rimzdkkxvg(vuuvcteoxh) = gqwpoqvwxw rdsjfjqmkn (slqecoadvm ) View more	Positive	10 Aug 2022
				Placebo	rimzdkkxvg(vuuvcteoxh) = ejdbtezxan rdsjfjqmkn (slqecoadvm ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lotiglipron

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation